Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04853251 · ClinicalTrials.gov registry record · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
A Phase 4 study of Neovascular Age-related Macular Degeneration, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT04853251: Recruiting Phase 4 study of Neovascular Age-related Macular Degeneration, sponsored by Genentech.
NCT04853251 is a Phase 4 study of Neovascular Age-related Macular Degeneration that is actively recruiting participants, run by Genentech. The registered enrollment target is 188 participants, below the 403-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04853251, a Phase 4 study of Neovascular Age-related Macular Degeneration, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
Conditions Studied
Interventions
- DEVICE PDS Implant With Ranibizumab 100 mg/ml
- DRUG LUCENTIS (Ranibizumab Injection)
Study Locations (20)
California
- California Retina Consultants - Bakersfield
- Retina Associates of Southern California - Huntington Beach
- California Eye Specialists Medical group Inc. - Pasadena
- Retinal Consultants Med Group - Sacramento
- University of California San Francisco - San Francisco
- Orange County Retina Med Group - Santa Ana
- Macula Retina Vitreous Research Institute - Torrance
Florida
- Retina Specialty Institute - Pensacola
- Ft Lauderdale Eye Institute - Plantation
- Retina Vitreous Associates of Florida - St. Petersburg
Colorado
- Southwest Retina Consultants - Durango
- Advanced Vision Research Institute - Longmont
Arizona
- Barnet Dulaney Perkins Eye Center - Mesa
Connecticut
- Retina Group of New England - Waterford
Georgia
- Southeast Retina Center - Augusta
Illinois
- University Retina and Macula Associates, PC - Lemont
Iowa
- Wolfe Eye Clinic - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 4 |
What NCT04853251 shows while recruiting
NCT04853251 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 403-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which PDS Implant With Ranibizumab 100 mg/ml is the first listed.
NCT04853251 names 20 study sites across 11 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT04853251 about?
NCT04853251 is a clinical study titled "A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)". This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
What is the current status of trial NCT04853251?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 188 participants. The study started on 2021-12-14. Estimated completion is 2028-04-30.
What conditions does trial NCT04853251 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT04853251?
The interventions under investigation include: PDS Implant With Ranibizumab 100 mg/ml (DEVICE), LUCENTIS (Ranibizumab Injection) (DRUG).
Who is sponsoring clinical trial NCT04853251?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04853251 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04853251's enrollment target sits among peer trials
188 13th of 33 higher than 21 of 33 other Neovascular Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
COMPLETED · Phase 4
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
RECRUITING · Phase 3
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT05076110 · 188 participants · Phase 4
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI